Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Debt (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Non-Current Debt data on record, last reported at $7.2 million in Q3 2025.

  • For Q3 2025, Non-Current Debt fell 65.27% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, down 65.27%, while the annual FY2024 figure was $12.4 million, 38.97% down from the prior year.
  • Non-Current Debt reached $7.2 million in Q3 2025 per NWBO's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $25.2 million in Q4 2021 and bottomed at $5.9 million in Q3 2022.
  • Average Non-Current Debt over 5 years is $13.8 million, with a median of $12.4 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: skyrocketed 290.64% in 2021, then plummeted 76.18% in 2022.
  • A 5-year view of Non-Current Debt shows it stood at $25.2 million in 2021, then tumbled by 76.18% to $6.0 million in 2022, then soared by 239.04% to $20.3 million in 2023, then plummeted by 38.97% to $12.4 million in 2024, then crashed by 42.01% to $7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $7.2 million in Q3 2025, $9.2 million in Q2 2025, and $7.1 million in Q1 2025.